Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Pinnacle Discovers Silver-Lead-Zinc Mineralization Following up on LiDAR Survey at El Potrero (click to learn more) Sekur Private Data Signs Distribution Agreement In Africa (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare Drug Manufacturers - Specialty & Generic
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for... see more

Current News (TSX:GUD)

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

GlobeNewswire 3 hours ago

Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil

GlobeNewswire 3 hours ago

Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call

GlobeNewswire 5 days ago

Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil

GlobeNewswire February 18, 2026

Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris

GlobeNewswire December 18, 2025

Knight Therapeutics Reports Third Quarter 2025 Results

GlobeNewswire November 6, 2025

Knight Announces Closing of US$100 Million Revolving Credit Facility

GlobeNewswire October 31, 2025

Knight Therapeutics Announces Launch of JORNAY PM(TM) in Canada

GlobeNewswire October 30, 2025

Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina

GlobeNewswire October 30, 2025
View More News ››

Opinion & Analysis (TSX:GUD)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSX:GUD)

CNBC CURES EVENT LIVESTREAM

Discussing how we are on edge of great drug discoveries . With All this tech, AI & overall biotech & pharma development, so much...
GoldenInvestor - 13 days ago

About her take on things that are happening

  What Is a Low Volume Pullback? A low-volume pullback is a technical correctiontoward an area of support that occurs on...
wofats - February 27, 2026

RE:Strong prospects seen by AI & general public

The Apotex IPO will be interesting to watch as a guage for investor appetite into the healthcare sector. Very possible that it trades at...
longrun86 - February 25, 2026

Strong prospects seen by AI & general public

& that is full AI based on public info, not including positive Momentum & positive developments that can come as operations...
GoldenInvestor - February 25, 2026

What others see when researching KNIGHT

Knight Therapeutics (TSX: GUD) stock is generally rated as a "Buy" or "Strong Buy" by analysts, with a 12-month...
GoldenInvestor - February 25, 2026

When it goes the other way

The opposite way The "death cross" is a market chart pattern reflecting recent price weakness. What Is a...
wofats - February 25, 2026
View more Bullboard ››

AKITA Drilling Ltd.

AKITA Drilling Ltd.

AKITA Drilling Ltd. operates as an oil and gas drilling contractor in Canada and the United States. It is involved in the ...
View More »

Podcasts